x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Pharma and BioTech Daily

Pharma and BioTech News

This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: https://www.buzzsprout.com/2189790

news tech news

All Episodes

8:29

Transformative Therapies: Innovations and Regulatory...

Pharma and BioTech Daily ·

2025/11/05

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets mult...

en-us

8:20

**Industry Shifts: Mergers, Regulations, and Biotech...

Pharma and BioTech Daily ·

2025/11/04

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout...

en-us

7:18

Precision Oncology and HIV Prevention Breakthroughs

Pharma and BioTech Daily ·

2025/11/03

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating advancements and strategic movements that are shaping the landscape of drug development and patient care.Starting with a significant milestone in precision oncology, China has approved its first EGFR-targeted antibody-drug conjugate. This approval marks a pivotal moment in the industry’s shift towards targeted the...

en-us

33:50

Week in Review November 1st

Pharma and BioTech Daily ·

2025/11/01

This Week in Review covers 5 episodes from October 27 to October 31, featuring major developments in the pharmaceutical and biotech industries. Episodes included: 1. Pharma Shifts: Dual-Action Obesity Drugs & Regulatory Waves 2. Navigating Pharma's New Frontiers: Breakthroughs and Challenges 3. Gene Therapy Challenges and Regulatory Shifts: Industry Innovations 4. Biotech Breakthroughs: Transformative Acquisitions and FDA Milestones 5. Novartis' $12B RNA Therapeutics Breakthrough Key topi...

en-us

7:12

Pharma Shifts: Dual-Action Obesity Drugs & Regulatory...

Pharma and BioTech Daily ·

2025/10/31

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reac...

en-us

6:20

Navigating Pharma's New Frontiers: Breakthroughs and...

Pharma and BioTech Daily ·

2025/10/30

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of significant developments that underscore the rapid evolution within these industries.Starting with one of the major players, Merck, which has been strategically adjusting its focus in light of Keytruda's looming loss of exclusivity. The company has demonstrated remarkable progress with Welireg in kidney cancer trials, successfu...

en-us

8:09

Gene Therapy Challenges and Regulatory Shifts:...

Pharma and BioTech Daily ·

2025/10/29

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavian, has garnered significant attention. Despite being the sole approved gene therapy for hemophilia A, Roctavian has struggled with sales since its ...

en-us

5:25

Biotech Breakthroughs: Transformative Acquisitions...

Pharma and BioTech Daily ·

2025/10/28

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This...

en-us

5:58

Novartis' $12B RNA Therapeutics Breakthrough

Pharma and BioTech Daily ·

2025/10/27

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis’s acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences h...

en-us

31:05

Week in Review - October 25, 2025

Pharma and BioTech Daily ·

2025/10/25

This week in review covers 5 episodes from October 20 to October 24, featuring major developments in pharmaceutical and biotech industries including strategic acquisitions, regulatory updates, and clinical trial results. Episodes included: 1. Pharma Innovations: AI's Impact and Strategic Shifts 2. Strategic Acquisitions and AI Revolutionize Pharma Landscape 3. Industry Shifts: Novo Nordisk's Revamp & ADC Breakthroughs 4. Transformative Advances in Precision Oncology and ADCs 5. Transforma...

en-us

6:15

Pharma Innovations: AI's Impact and Strategic Shifts

Pharma and BioTech Daily ·

2025/10/24

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care.Starting with Merck KGaA, their decision to close the Active Pharmaceutical Ingredient plant in Arklow, Ireland by 2028 marks a pivotal shift in their manufacturing strategy. This move follows a strategic review and is emblematic of broad...

en-us

5:34

Strategic Acquisitions and AI Revolutionize Pharma...

Pharma and BioTech Daily ·

2025/10/23

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape.Let's begin with a significant acquisition that is resonating across the sector. Alkermes has strategically acquired Avadel Pharmaceuticals for a noteworthy $2.1 billion. This acquisition is primarily aimed at Avadel's long-acting narcolepsy drug, Lumryz. This mov...

en-us

6:13

Industry Shifts: Novo Nordisk's Revamp & ADC...

Pharma and BioTech Daily ·

2025/10/22

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones, and groundbreaking scientific advancements that are shaping the future of drug development and patient care.Let's begin with a major corporate shakeup at Novo Nordisk. The company has announced a significant lead...

en-us

6:26

Transformative Advances in Precision Oncology and ADCs

Pharma and BioTech Daily ·

2025/10/21

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trod...

en-us

5:51

Transformative Oncology Breakthroughs and Regulatory...

Pharma and BioTech Daily ·

2025/10/20

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, where key clinical trial outcomes have emerged, potentially reshaping future treatment protocols.AstraZeneca made waves with its Phase 3 trial resu...

en-us

30:10

Week in review October 18th 2025

Pharma and BioTech Daily ·

2025/10/18

This Week in Review covers episodes from October 14 to October 17, featuring major developments in the pharmaceutical and biotech industries. Episodes included: Biotech Breakthroughs: Partnerships, AI, and Clinical TriumphsPharma Breakthroughs: Advancing Cancer, Diabetes, and HIV CareNavigating Regulatory Shifts and Strategic Mergers in BiotechRevolutionizing Care: Key Biotech Breakthroughs and TrendsKey topics covered: Strategic acquisitions and partnershipsRegulatory updates and FDA approva...

en-us

9:40

Biotech Breakthroughs: Partnerships, AI, and Clinical...

Pharma and BioTech Daily ·

2025/10/17

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of fascinating updates that underscore a period of significant scientific advancement, strategic partnerships, and regulatory developments in the industry.Starting with Dianthus Therapeutics, which has taken a bold step by investing up to $1 billion to license a bifunctional fusion protein from Nanjing Leads Biolabs. This prote...

en-us

5:26

Pharma Breakthroughs: Advancing Cancer, Diabetes, and...

Pharma and BioTech Daily ·

2025/10/16

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of major advancements and strategic moves that are shaping the future of healthcare.A significant development comes from AstraZeneca, which has committed a substantial $445 million investment to bolster production at its Texas facility for Lokelma, a treatment designed for hyperkalemia. Hyperkalemia is a condition characterized ...

en-us

6:46

Navigating Regulatory Shifts and Strategic Mergers in...

Pharma and BioTech Daily ·

2025/10/15

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the rapidly evolving landscape of the pharmaceutical and biotech sectors, where regulatory updates, strategic mergers, and scientific breakthroughs are continually reshaping the industry.Starting with Novo Nordisk's recent challenges, their newly acquired manufacturing facility in Indiana has been flagged by the FDA with an "Official Action Ind...

en-us

7:34

Revolutionizing Care: Key Biotech Breakthroughs and...

Pharma and BioTech Daily ·

2025/10/14

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest news shaping this dynamic industry.Bristol Myers Squibb recently made headlines with their acquisition of Orbital Therapeutics for a remarkable $1.5 billion. This strategic move is aimed at enhancing their in vivo cell therapy capabilities, particularly in treating autoimmune disorders. In vivo cell therapy is a pioneering approach tha...

en-us

425 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS NewsHour

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci